Skip to main content

Table 1 Pretreatment CA125 level >35 U/mL in epithelial ovarian cancer. Relationship between histological subtype and FIGO stage

From: High levels of pretreatment CA125 are associated to improved survival in high grade serous ovarian carcinoma

 

Histological subtypes

 

FIGO Stage

Serous

Endometrioid

Mucinous

Clear Cell

Mixed

Total

I

8/9

30/37

16/22

12/18

9/10

75/96

89 %

81 %

73 %

67 %

90 %

78 %

231 U/mL

137 U/mL

113 U/mL

153 U/mL

305 U/mL

 

II

3/4

6/8

1/1

1/1

2/2

13/16

75 %

75 %

100 %

100 %

100 %

81 %

90 U/mL

281 U/mL

75 U/mL

1042 U/mL

252 U/mL

 

III

116/118

35/36*

6/10

11/11*

27/28

195/203

98 %

97 %

60 %

100 %

96 %

96 %

1255 U/mL

861 U/mL

195 U/mL

415 U/mL

1182 U/mL

 

IV

137/137*

13/13

4/6

7/8

10/10

171/174

100 %

100 %

67 %

88 %

100 %

98 %

2005 U/mL

511 U/mL

144 U/mL

376 U/mL

1240 U/mL

 

Total

264/268

84/94

27/39***

31/38

48/50

 

99 %

89 %

69 %

82 %

96 %

 
  1. Values indicate the proportion and percentage of patients with abnormal CA125 and the means of pretreatment values of CA125 U/mL. Comparison of proportions (“Z”)
  2. *P < 0.05 versus FIGO stage I; ***P < 0.001 vs serous and P < 0.01 vs. endometrioid total values